This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat and manage patients with UC.
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for treatment of UC.
Upon completion of this activity, participants should be able to:
Integrate into practice predictive biomarkers to inform personalized patient care
Plan adjuvant therapy for patients with high-risk urothelial carcinoma following radical resection
Integrate checkpoint inhibitor therapies into practice to optimize the care of patients with advanced urothelial carcinoma considering the available evidence and patient and disease characteristics
Select evidence-based targeted therapy approaches for patients with disease progression during or following platinum-containing chemotherapy and/or immune checkpoint inhibitor therapy
Navigate barriers and racial disparities in care to identify and enroll qualified patients in ongoing clinical trials actively investigating targeted systemic therapies and immune checkpoint inhibitor–based regimens for patients across the disease spectrum
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Terence Friedlander, MD
Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
Chief of Hematology-Oncology
Zuckerberg San Francisco General Hospital
San Francisco, California
Terence Friedlander, MD: consultant/advisor/speaker: AADi, Astellas, Seagen; researcher: Roche, Seagen, Trishula.
The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from September 13, 2023, through September 12, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
The program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008176-0000-23-239-H01-P
Type of Activity: Application
Upon successfully completing the post-test with a score of 65 or better and the activity evaluation form, transcript information will be sent to NABP CPE Monitor Services within 60 days.